Inactief instrument

Andere talen Respirerx Pharmaceuticals Inc Other OTC

Aandelen

US2205243007

slotkoers Other OTC Andere beurzen
- ^USD	-

20/03	RespireRx Pharmaceuticals Inc. rapporteert de publicatie van preklinische onderzoeksresultaten die het vermogen aantonen van CX1739, de voornaamste klinische AMPAkine, om de blaasfunctie te verbeteren na ruggenmergletsel	CI
13/02	RespireRx Pharmaceuticals Inc. rapporteert preklinische pijnverlichting voor hun niet-Opioïde lead GABAkine	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	10/04
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	20/03
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	20/03
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine	13/02
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine	13/02
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors	22/01
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors	22/01
RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	04/01
Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	04/01
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development	11/12
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11
Today's Top OTC Stocks Watchlist (SWISF, EPAZ, ABQQ, RSPI)	13-10-23
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services	12-10-23
RespireRx Pharmaceuticals : SETTLEMENT AND EXCHANGE AGREEMENT - Form 8-K	02-10-23
Attention Deficit Hyperactivity Disorder Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	26-09-23
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21-08-23
CapitalGainsReport: Sub Penny Stocks Set To Soar: EPAZ, RSPI, TPTW, HGEN	10-08-23
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company	09-08-23
RespireRx Pharmaceuticals : Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Plan - Form 8-K	13-06-23
RESPIRERX PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	13-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Respirerx Pharmaceuticals Inc Other OTC

Aandelen

US2205243007

Andere talen

Filters